273 related articles for article (PubMed ID: 19695075)
21. Glycemic Control Modifies Difference in Mortality Risk Between Hemodialysis and Peritoneal Dialysis in Incident Dialysis Patients With Diabetes: Results From a Nationwide Prospective Cohort in Korea.
Lee MJ; Kwon YE; Park KS; Kee YK; Yoon CY; Han IM; Han SG; Oh HJ; Park JT; Han SH; Yoo TH; Kim YL; Kim YS; Yang CW; Kim NH; Kang SW
Medicine (Baltimore); 2016 Mar; 95(11):e3118. PubMed ID: 26986162
[TBL] [Abstract][Full Text] [Related]
22. Gender differences in clinical outcomes among diabetic patients hospitalized for cardiovascular disease.
Flink L; Mochari-Greenberger H; Mosca L
Am Heart J; 2013 Jun; 165(6):972-8. PubMed ID: 23708169
[TBL] [Abstract][Full Text] [Related]
23. Glycated hemoglobin variability and the risk of cardiovascular events in patients with prediabetes and type 2 diabetes mellitus: A post-hoc analysis of a prospective and multicenter study.
Manosroi W; Phimphilai M; Waisayanand N; Buranapin S; Deerochanawong C; Gunaparn S; Phrommintikul A; Wongcharoen W;
J Diabetes Investig; 2023 Dec; 14(12):1391-1400. PubMed ID: 37610280
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Survivor Characteristics in Hemodialysis Patients with Type 2 Diabetes.
Triebswetter S; Gutjahr-Lengsfeld LJ; Schmidt KR; Drechsler C; Wanner C; Krane V
Am J Nephrol; 2018; 47(1):30-39. PubMed ID: 29320770
[TBL] [Abstract][Full Text] [Related]
25. The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease.
Bots SH; van der Graaf Y; Nathoe HM; de Borst GJ; Kappelle JL; Visseren FL; Westerink J;
Cardiovasc Diabetol; 2016 Jul; 15(1):101. PubMed ID: 27431507
[TBL] [Abstract][Full Text] [Related]
26. Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose.
Lin CC; Chen CC; Chen FN; Li CI; Liu CS; Lin WY; Yang SY; Lee CC; Li TC
Am J Med; 2013 Nov; 126(11):1017.e1-10. PubMed ID: 23993260
[TBL] [Abstract][Full Text] [Related]
27. HbA
Metcalf PA; Kyle C; Kenealy T; Jackson RT
J Diabetes Complications; 2017 May; 31(5):814-823. PubMed ID: 28319002
[TBL] [Abstract][Full Text] [Related]
28. The relation between HbA1c and cardiovascular events in patients with type 2 diabetes with and without vascular disease.
Kranenburg G; van der Graaf Y; van der Leeuw J; Nathoe HM; de Borst GJ; Kappelle LJ; Visseren FL; Westerink J;
Diabetes Care; 2015 Oct; 38(10):1930-6. PubMed ID: 26307606
[TBL] [Abstract][Full Text] [Related]
29. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
[TBL] [Abstract][Full Text] [Related]
30. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR).
Eeg-Olofsson K; Cederholm J; Nilsson PM; Zethelius B; Svensson AM; Gudbjörnsdóttir S; Eliasson B
J Intern Med; 2010 Nov; 268(5):471-82. PubMed ID: 20804517
[TBL] [Abstract][Full Text] [Related]
31. Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients.
Yamashita T; Okano K; Tsuruta Y; Akiba T; Nitta K
Int Urol Nephrol; 2013 Feb; 45(1):207-14. PubMed ID: 22447111
[TBL] [Abstract][Full Text] [Related]
32. Hemoglobin A1c Level and Cardiovascular Disease Incidence in Persons With Type 1 Diabetes: An Application of Joint Modeling of Longitudinal and Time-to-Event Data in the Pittsburgh Epidemiology of Diabetes Complications Study.
Miller RG; Anderson SJ; Costacou T; Sekikawa A; Orchard TJ
Am J Epidemiol; 2018 Jul; 187(7):1520-1529. PubMed ID: 29394305
[TBL] [Abstract][Full Text] [Related]
33. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study.
Penno G; Solini A; Zoppini G; Orsi E; Fondelli C; Zerbini G; Morano S; Cavalot F; Lamacchia O; Trevisan R; Vedovato M; Pugliese G;
Cardiovasc Diabetol; 2013 Jul; 12():98. PubMed ID: 23829205
[TBL] [Abstract][Full Text] [Related]
34. Greater HbA1c variability is associated with increased cardiovascular events in type 2 diabetes patients with preserved renal function, but not in moderate to advanced chronic kidney disease.
Lee MY; Hsiao PJ; Huang YT; Huang JC; Hsu WH; Chen SC; Shin SJ
PLoS One; 2017; 12(6):e0178319. PubMed ID: 28591149
[TBL] [Abstract][Full Text] [Related]
35. Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study.
Liao LN; Li CI; Liu CS; Huang CC; Lin WY; Chiang JH; Lin CC; Li TC
PLoS One; 2015; 10(6):e0130828. PubMed ID: 26098901
[TBL] [Abstract][Full Text] [Related]
36. Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis.
Shima K; Komatsu M; Kawahara K; Minaguchi J; Kawashima S
Nephrology (Carlton); 2010 Sep; 15(6):632-8. PubMed ID: 20883284
[TBL] [Abstract][Full Text] [Related]
37. Glycated albumin versus glycated hemoglobin as glycemic indicator in hemodialysis patients with diabetes mellitus: variables that influence.
Sany D; Elshahawy Y; Anwar W
Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):260-73. PubMed ID: 23538348
[TBL] [Abstract][Full Text] [Related]
38. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease.
Okada T; Nakao T; Matsumoto H; Shino T; Nagaoka Y; Tomaru R; Wada T
Intern Med; 2007; 46(12):807-14. PubMed ID: 17575371
[TBL] [Abstract][Full Text] [Related]
39. Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study.
Sasso FC; Lascar N; Ascione A; Carbonara O; De Nicola L; Minutolo R; Salvatore T; Rizzo MR; Cirillo P; Paolisso G; Marfella R;
Cardiovasc Diabetol; 2016 Oct; 15(1):147. PubMed ID: 27733159
[TBL] [Abstract][Full Text] [Related]
40. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A(1c).
Uzu T; Hatta T; Deji N; Izumiya T; Ueda H; Miyazawa I; Kanasaki M; Isshiki K; Nishio T; Arimura T
Ther Apher Dial; 2009 Apr; 13(2):89-94. PubMed ID: 19379146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
